Search Results

Press Releases

Hovione and Zerion Pharma create joint venture to further expand use of Dispersome® technology

October 3, 2024

·

1 min read

Business

Hovione and Laxxon Medical Establish an Agreement for the cGMP Production of 3D Screen Printed Pharmaceutical Applications

Hovione and Laxxon Medical announced a strategic collaboration to advance the use of 3D screen printing technologies for the pharmaceutical industry.

March 27, 2023

·

4 min read

Hovione and H&T Presspart extend partnership to advance high efficiency device technology for Dry Powder Inhalation formulation delivery

Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and H&T Presspart have entered in a strategic partnership to advance the development of Presspart’s Sunriser© Capsule-based Dry Powder Inhaler platform.

May 3, 2023

·

4 min read

Hovione expands drug product offering with a new manufacturing line dedicated to Continuous Tableting

Hovione, the leader in spray drying and particle engineering, announced that it has expanded its continuous manufacturing offering and services.

September 6, 2022

·

3 min read

Zerion Pharma and Hovione extend partnership to cover use of the Dispersome® technology platform in nutraceuticals

AUGUST 23, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (ZERION) and Hovione today announced an extension of their collaboration on ZERION’s Dispersome® technology into the nutraceutical/dietary supplements field. Many dietary supplements suffer from low solubility.

August 23, 2022

·

5 min read

Business

Hovione Announces Partnership to Support Manufacturing of Antiviral Veklury® for COVID-19

Hovione today announced the signing of a partnership agreement with Ligand to significantly ramp up the production output of Captisol®

September 23, 2020

·

3 min read

Business

Hovione Announces the Appointment of Jean-Luc Herbeaux as Chief Operating Officer

Hovione announced today the appointment of Dr. Jean-Luc Herbeaux as Chief Operating Officer, effective May 1st, 2020.

May 4, 2020

·

2 min read

Drug Development

Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction

Hovione announced at the Ophthalmology Innovation Summit (OIS) Dry Eye Showcase the successful completion of its Phase 2 clinical trial in 270 patients with Dry Eye caused by Meibomian Gland Dysfunction (MGD).

March 17, 2021

·

4 min read

Hovione Issues $50 Million Bond

Hovione has issued a bond of $50 million US dollars maturing in 2033.

January 25, 2019

·

1 min read

Zerion Pharma and Hovione form strategic partnership to market and commercialise the proprietary Dispersome® technology platform

This unique combination provides customers in the pharma industry with a line of sight over the entire drug development life cycle from the preclinical phase to commercial drug product.

February 22, 2022

·

4 min read